| | PPAR agonist + antitumor agent | PPAR | Tumor type | Molecular mediator(s) of apoptosis | Reference |
| | Troglitazone or ciglitazone or
GW1929 + TRAIL | Independent | Lung | DR5, c-FLIP | [34] | | 15d-PGJ2 + TRAIL | Independent | Leukemia, prostate | DR5 | [47] | | Troglitazone + TRAIL | Independent | Glioblastoma, neuroblastoma | c-FLIP, survivin, DR5 | [52] | | Rosiglitazone + TRAIL | Independent | Renal, glioma, breast, prostate | ROS, DR5, c-FLIP | [49] | | 15d-PGJ2 or ciglitazone
or troglitazone or CDDO or CDDO-Me + TRAIL | Independent | Prostate, ovarian, colon | c-FLIP | [50] | | Troglitazone + TRAIL or troglitazone
+ etoposide or paclitaxel | Independent | Glioma | PTP1B, STAT3, c-FLIP, Bcl-2 | [53] | | 15d-PGJ2 + MK886 | Dependent | Lung | PPAR, RXR | [54] | | 15d-PGJ2 + Indomethacin | | Ciglitazone + MK886 +
13-cis-retinoic acid | | Rosiglitazone + LG100268 or all
transretinoic acid | Dependent and independent | Leukemia, lymphoma, myeloma | Bcl-2, caspase-9 | [55] | | 15d-PGJ2 + LG100268 or
all trans-retinoic acid | | CDDO + LG100268 or all transretinoic
acid | | Rosiglitazone + carboplatin | Dependent | Lung, ovarian, colon | MT1H, MT1X, MTIIA | [56] | | TZD18 + imatinib | Independent | Leukemia | Bax, NF-B | [57, 58] | | RS5444 + paclitaxel | Dependent | Thyroid | p21WAF1/CIP1 | [59] | | 15dPGJ2 + docetaxel | Independent | Lung | Bcl-2, BAD, cyclin D1, p53 | [60] |
|
|
